VDAC1 Platform
Type 2 Diabetes
Key Facts
About Abarceo Pharma
Abarceo Pharma is a Swedish, preclinical-stage biotechnology company founded on pioneering research from Lund University. Its core technology targets the mitochondrial protein VDAC1, aiming to reverse beta-cell dysfunction in Type 2 Diabetes and potentially treat other conditions like Alzheimer's Disease and cardiovascular disease. The company is led by a CEO with entrepreneurial experience and founded by world-renowned diabetes researchers, positioning it to address multi-billion-euro markets with high unmet need. Abarceo is currently establishing preclinical proof-of-concept across its initial target indications.
View full company profileAbout Abarceo Pharma
Abarceo Pharma is a Swedish, preclinical-stage biotechnology company founded on pioneering research from Lund University. Its core technology targets the mitochondrial protein VDAC1, aiming to reverse beta-cell dysfunction in Type 2 Diabetes and potentially treat other conditions like Alzheimer's Disease and cardiovascular disease. The company is led by a CEO with entrepreneurial experience and founded by world-renowned diabetes researchers, positioning it to address multi-billion-euro markets with high unmet need. Abarceo is currently establishing preclinical proof-of-concept across its initial target indications.
View full company profileAbout Abarceo Pharma
Abarceo Pharma is a Swedish, preclinical-stage biotechnology company founded on pioneering research from Lund University. Its core technology targets the mitochondrial protein VDAC1, aiming to reverse beta-cell dysfunction in Type 2 Diabetes and potentially treat other conditions like Alzheimer's Disease and cardiovascular disease. The company is led by a CEO with entrepreneurial experience and founded by world-renowned diabetes researchers, positioning it to address multi-billion-euro markets with high unmet need. Abarceo is currently establishing preclinical proof-of-concept across its initial target indications.
View full company profileOther Type 2 Diabetes Drugs
| Drug | Company | Phase |
|---|---|---|
| Diabetes Management Gel | Gelteq Limited | Formulation Development |
| Tolimidone | Biodexa Pharmaceuticals | Phase 2 |
| Generic Semaglutide Injection (Obeda) | Dr. Reddy's Laboratories | Approved |
| BioChaperone® Lispro | Adocia | Phase 3 |
| BioChaperone® Combo (Insulin Glargine / Lixisenatide) | Adocia | Phase 2 |
| Metformin API | USV Biologics Division | Commercial |
| Empagliflozin | Azico Biophore | Commercial |
| Sitagliptin Intermediate | AR Life Science | Commercial |
| AJN003 (LuCI™) | AltrixBio | Pre-clinical |
| Sitagliptin Phosphate Polymorph | Morepen Laboratories | Pre‑clinical |
| Hepatic Denervation for Type 2 Diabetes | Metavention | Feasibility |
| MVD-1 (SANA) | Eolo Pharma | Discovery |